Jazz Pharmaceuticals plc — Director's Dealing 2016

Jan 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-01-05

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-05	Ordinary Shares	S	5746	$137.7086	Disposed	229538	Indirect
2016-01-05	Ordinary Shares	S	2843	$138.3646	Disposed	226695	Indirect
2016-01-05	Ordinary Shares	S	1214	$139.2447	Disposed	225481	Indirect
2016-01-05	Ordinary Shares	S	116	$137.7073	Disposed	4600	Indirect
2016-01-05	Ordinary Shares	S	57	$138.3654	Disposed	4543	Indirect
2016-01-05	Ordinary Shares	S	24	$139.2387	Disposed	4519	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	1310	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.06 to $138.0573. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. except to the extent of his pecuniary interest therein.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $138.0887 to $138.9478. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.09 to $139.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.06 to $138.0573. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $138.0887 to $138.9478. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.09 to $139.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.